You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The investment bank noted the potential of Alere's new MDx platforms, but said that Quest's potential could suffer in comparison to its competitor LabCorp.
The firm used about $1.68 billion of proceeds from the new term loans to repay existing secured credit facilities and transaction expenses.
Proceeds from the offering will be used to redeem $400 million outstanding in senior notes due 2018.
The company also restated its financial results for full-year 2014 and for the third quarter of 2014.
Alere missed the deadline to file its Form 10-Q as a result of having to restate its 2014 and interim financial results, prompting the warning from the NYSE.
Under the agreement, Abbott will create tests for two protein biomarkers that AstraZeneca hopes can predict asthma patients' response to its investigational drug tralokinumab.
The firm also said that it will restate its 2014 financial statements due to "errors related to the accounting for income taxes in our discontinued operations."
Abbott's first quarter diagnostic revenues decreased around 2 percent year over year, although its molecular diagnostic sales inched up a fraction of a percent.
The system uses off-the-shelf laboratory components and currently runs an Ebola assay based on isothermal amplification chemistry from Alere subsidiary TwistDx.
The deal includes PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.